Translatome analysis of tuberous sclerosis complex 1 patient-derived neural progenitor cells reveals rapamycin-dependent and independent alterations
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Translatome analysis of tuberous sclerosis complex 1 patient-derived neural progenitor cells reveals rapamycin-dependent and independent alterations ; volume:14 ; number:1 ; day:25 ; month:10 ; year:2023 ; pages:1-20 ; date:12.2023
Molecular autism ; 14, Heft 1 (25.10.2023), 1-20, 12.2023
- Creator
-
Aksoylu, Inci S.
Martin, Pauline
Robert, Francis
Szkop, Krzysztof J.
Redmond, Nicholas E.
Bhattacharyya, Srirupa
Wang, Jennifer
Chen, Shan
Beauchamp, Roberta L.
Nobeli, Irene
Pelletier, Jerry
Larsson, Ola
Ramesh, Vijaya
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13229-023-00572-3
- URN
-
urn:nbn:de:101:1-2024020908012198687632
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:38 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Aksoylu, Inci S.
- Martin, Pauline
- Robert, Francis
- Szkop, Krzysztof J.
- Redmond, Nicholas E.
- Bhattacharyya, Srirupa
- Wang, Jennifer
- Chen, Shan
- Beauchamp, Roberta L.
- Nobeli, Irene
- Pelletier, Jerry
- Larsson, Ola
- Ramesh, Vijaya
- SpringerLink (Online service)
Other Objects (12)
TSC patient-derived isogenic neural progenitor cells reveal altered early neurodevelopmental phenotypes and rapamycin-induced MNK-eIF4E signaling
Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models
Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779
Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex
Optimization, Formulation, and Stability of Topical Rapamycin Used for Rare Tuberous Sclerosis Disease: from Ointment to Liposomes
Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
Rapamycin retards growth and causes marked alterations in the growth plate of young rats
Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up
Screening drug effects in patient‐derived cancer cells links organoid responses to genome alterations
TSC patient-derived isogenic neural progenitor cells reveal altered early neurodevelopmental phenotypes and rapamycin-induced MNK-eIF4E signaling
Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models
Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779
Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex
Optimization, Formulation, and Stability of Topical Rapamycin Used for Rare Tuberous Sclerosis Disease: from Ointment to Liposomes
Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
Rapamycin retards growth and causes marked alterations in the growth plate of young rats
Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up
Screening drug effects in patient‐derived cancer cells links organoid responses to genome alterations
TSC patient-derived isogenic neural progenitor cells reveal altered early neurodevelopmental phenotypes and rapamycin-induced MNK-eIF4E signaling
Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models
Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779
Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex
Optimization, Formulation, and Stability of Topical Rapamycin Used for Rare Tuberous Sclerosis Disease: from Ointment to Liposomes
Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
Rapamycin retards growth and causes marked alterations in the growth plate of young rats
Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up